Reading Time: < 1 minute
Enter a captionGilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in sales from preventative HIV drug Truvada, despite the fact it was developed by the US government.
While the American government patented the PrEP drug in 2015, the government has not received a single penny in royalties from Foster City-based Gilead Sciences.
Nevertheless Gilead charge between $1,600 and $2,000 a month for Truvada. Meanwhile, generic versions of the drug are sold for as little as £20 for a month’s supply in the UK. Read More